Genedrive (GDR)

Sector:

Health Care

Index:

FTSE AIM All-Share

3.38p
   
  • Change Today:
      0.13p
  • 52 Week High: 36.75
  • 52 Week Low: 2.56
  • Currency: UK Pounds
  • Shares Issued: 138.45m
  • Volume: 2,184,986
  • Market Cap: £4.67m
  • RiskGrade: 747

Genedrive to seek CE mark clearance for MT-RNR1 assay

By Iain Gilbert

Date: Wednesday 27 Oct 2021

LONDON (ShareCast) - (Sharecast News) - Molecular diagnostics company Genedrive said on Tuesday that it will soon launch its MT-RNR1 assay, used for the detection of antibiotic-induced hearing loss in newborns.
Genedrive stated the MT-RNR1 assay will target the m.1555A>G mutation genotype, which if a baby carrying the mutation is given the antibiotic gentamicin, can cause lifelong deafness.

The AIM-listed firm said a large-scale implementation trial of the MT-RNR1 assay was performed on 750 newborns by Manchester and Liverpool Hospitals, representing the world's first use of a genetic point of care test in a neonatal intensive care setting and leading the firm to make improvements to the test's cartridge, instrument interface and data management options.

Genedrive will be seeking CE mark clearance for the new system in "the coming weeks" prior to commercial launch.

Chief executive David Budd said: "It has been very rewarding to see the positive effect of point of care AIHL testing, and the feedback and engagement of the NHS teams has been a tangible benefit to the Company and will ultimately be a key driver of adoption in the market place.

"Following this refinement of the overall AIHL system, we are looking forward to the impending commercial launch and the improved healthcare outcomes it will offer as an innovative point of care test in a NICU care setting."

As of 1335 BST, Genedrive shares were up 3.26% at 47.50p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Genedrive Market Data

Currency UK Pounds
Share Price 3.38p
Change Today 0.13p
% Change 3.85 %
52 Week High 36.75
52 Week Low 2.56
Volume 2,184,986
Shares Issued 138.45m
Market Cap £4.67m
RiskGrade 747

Genedrive Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
31.48% below the market average31.48% below the market average31.48% below the market average31.48% below the market average31.48% below the market average
18.75% below the sector average18.75% below the sector average18.75% below the sector average18.75% below the sector average18.75% below the sector average
Price Trend
96% below the market average96% below the market average96% below the market average96% below the market average96% below the market average
94.59% below the sector average94.59% below the sector average94.59% below the sector average94.59% below the sector average94.59% below the sector average
Income Not Available
Growth
46.28% below the market average46.28% below the market average46.28% below the market average46.28% below the market average46.28% below the market average
77.78% below the sector average77.78% below the sector average77.78% below the sector average77.78% below the sector average77.78% below the sector average

Genedrive Dividends

No dividends found

Trades for 28-Mar-2024

Time Volume / Share Price
16:25 8,432 @ 3.17p
16:18 1,952 @ 3.17p
16:11 50,000 @ 3.20p
16:01 2,285 @ 3.18p
15:54 9,209 @ 3.18p

Genedrive Key Personnel

CFO Russell Shaw
CEO James Cheek

Top of Page